Top

Current Neurology and Neuroscience Reports

Published in:

01-06-2012 | Genetics (V Bonifati, Section Editor)

Schizophrenia Genetics: Putting All the Pieces Together

Authors: Simon L. Girard, Patrick A. Dion, Guy A. Rouleau

Published in: Current Neurology and Neuroscience Reports | Issue 3/2012

Abstract

Schizophrenia is a major mental disorder characterized by a deep disruption of the thinking process and of emotional response. For many decades, genetics studies have yielded little success in identifying genetic factors responsible for the disease. However, with the recent breakthroughs in genome analysis technologies, the field of the genetics of schizophrenia has progressed a lot in the last years. Both common and rare variants have been successfully associated with the disease and a particular emphasis has been made on rare copy number variations. Recently, a new paradigm linking de novo mutations to the genetic mechanism of schizophrenia has been unravelled. The aim of this review is to discuss the most important genetic studies made in the field to give a general perspective of where to go in the future.

van Os J, Kapur S. Schizophrenia. Lancet. 2009;374(9690):635–45.PubMedCrossRef

Tienari P. Schizophrenia in Finnish male twins. In: Lader MH, editor. Studies of schizophrenia. 1975. pp. 29–35.

Fischer M, Harvald B, Hauge M. A Danish twin study of schizophrenia. Br J Psychiatry. 1969;115(526):981–90.PubMedCrossRef

Kendler KS, Robinette CD. Schizophrenia in the National Academy of Sciences-National Research Council Twin Registry: a 16-year update. Am J Psychiatry. 1983;140(12):1551–63.PubMed

Onstad S, Skre I, Torgersen S, Kringlen E. Twin concordance for DSM-III-R schizophrenia. Acta Psychiatr Scand. 1991;83(5):395–401.PubMedCrossRef

Cannon TD, Kaprio J, Lönnqvist J, Huttunen M, Koskenvuo M. The genetic epidemiology of schizophrenia in a Finnish twin cohort. A population-based modeling study. Arch Gen Psychiatry. 1998;55(1):67–74.PubMedCrossRef

Cardno AG, Marshall EJ, Coid B, et al. Heritability estimates for psychotic disorders: the Maudsley twin psychosis series. Arch Gen Psychiatry. 1999;56(2):162–8.PubMedCrossRef

Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry. 2003;60(12):1187–92.PubMedCrossRef

Riley B. Linkage studies of schizophrenia. Neurotox Res. 2004;6(1):17–34.PubMedCrossRef

10.

Pulver AE, Karayiorgou M, Wolyniec PS, et al. Sequential strategy to identify a susceptibility gene for schizophrenia: report of potential linkage on chromosome 22q12-q13.1: part 1. Am J Med Genet. 1994;54(1):36–43.PubMedCrossRef

11.

Stefansson H, Sigurdsson E, Steinthorsdottir V, et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet. 2002;71(4):877–92.PubMedCrossRef

12.

Petryshen TL, Middleton FA, Kirby A, et al. Support for involvement of neuregulin 1 in schizophrenia pathophysiology. Mol Psychiatry. 2005;10(4):366–74. 328.PubMedCrossRef

13.

Seshadri S, Kamiya A, Yokota Y, et al. Disrupted-in-Schizophrenia-1 expression is regulated by beta-site amyloid precursor protein cleaving enzyme-1-neuregulin cascade. Proc Natl Acad Sci U S A. 2010;107(12):5622–7.PubMedCrossRef

14.

Bray NJ, Preece A, Williams NM, et al. Haplotypes at the dystrobrevin binding protein 1 (DTNBP1) gene locus mediate risk for schizophrenia through reduced DTNBP1 expression. Hum Mol Genet. 2005;14(14):1947–54.PubMedCrossRef

15.

Blackwood DH, Fordyce A, Walker MT, et al. Schizophrenia and affective disorders–cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a family. Am J Hum Genet. 2001;69(2):428–33.PubMedCrossRef

16.

Millar JK, Wilson-Annan JC, Anderson S, et al. Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum Mol Genet. 2000;9(9):1415–23.PubMedCrossRef

17.

Brandon NJ, Millar JK, Korth C, et al. Understanding the role of DISC1 in psychiatric disease and during normal development. J Neurosci. 2009;29(41):12768–75.PubMedCrossRef

18.

Betcheva ET, Mushiroda T, Takahashi A, et al. Case–control association study of 59 candidate genes reveals the DRD2 SNP rs6277 (C957T) as the only susceptibility factor for schizophrenia in the Bulgarian population. J Hum Genet. 2009;54(2):98–107.PubMedCrossRef

19.

Shifman S, Johannesson M, Bronstein M, et al. Genome-wide association identifies a common variant in the reelin gene that increases the risk of schizophrenia only in women. PLoS Genet. 2008;4(2):e28.PubMedCrossRef

20.

Kirov G, Zaharieva I, Georgieva L, et al. A genome-wide association study in 574 schizophrenia trios using DNA pooling. Mol Psychiatry. 2009;14(8):796–803.PubMedCrossRef

21.

Sullivan PF, Lin D, Tzeng JY, et al. Genomewide association for schizophrenia in the CATIE study: results of stage 1. Mol Psychiatry. 2008;13(6):570–84.PubMedCrossRef

22.

O’Donovan MC, Craddock N, Norton N, et al. Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet. 2008;40(9):1053–5.PubMedCrossRef

23.

Steinberg S, Mors O, Borglum AD, et al. Expanding the range of ZNF804A variants conferring risk of psychosis. Mol Psychiatry. 2010;16(1):59–66.

24.

Riley B, Thiselton D, Maher BS, et al. Replication of association between schizophrenia and ZNF804A in the Irish Case–control Study of Schizophrenia sample. Mol Psychiatry. 2010;15(1):29–37.PubMedCrossRef

25.

Hill MJ, Jeffries AR, Dobson RJB, Price J, Bray NJ. Knockdown of the psychosis susceptibility gene ZNF804A alters expression of genes involved in cell adhesion. Hum Mol Genet. 2011;21(5):1018–24.

26.

• Stefansson H, Ophoff RA, Steinberg S, et al. Common variants conferring risk of schizophrenia. Nature. 2009;460(7256):744–7. This is one of the first GWAS that identified the MHC as an associated region.PubMed

27.

• Purcell SM, Wray NR, Stone JL, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009;460(7256):748–52. This is one of the first GWAS that identified the MHC as an associated region.PubMed

28.

Handel AE, Ramagopalan SV. The potential role of major histocompatibility complex class I in schizophrenia. Biol Psychiatry. 2010;68(7):e29–30. author reply e31.PubMedCrossRef

29.

Shi Y, Li Z, Xu Q, et al. Common variants on 8p12 and 1q24.2 confer risk of schizophrenia. Nat Genet. 2011;43(12):1224–7.PubMedCrossRef

30.

Yue W-H, Wang H-F, Sun L-D, et al. Genome-wide association study identifies a susceptibility locus for schizophrenia in Han Chinese at 11p11.2. Nat Genet. 2011;43(12):1228–31.PubMedCrossRef

31.

•• Ripke S, Sanders AR, Kendler KS, et al. Genome-wide association study identifies five new schizophrenia loci. Nat Genet. 2011;43(10):969–76. This is the largest GWAS made on a SCZ cohort. It identifies MIR137 as an associated locus.PubMedCrossRef

32.

Balaguer F, Link A, Lozano JJ, et al. Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis. Cancer Res. 2010;70(16):6609–18.PubMedCrossRef

33.

Liu M, Lang N, Qiu M, et al. miR-137 targets Cdc42 expression, induces cell cycle G1 arrest and inhibits invasion in colorectal cancer cells. Int J Cancer. 2011;128(6):1269–79.PubMedCrossRef

34.

Silber J, Lim DA, Petritsch C, et al. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med. 2008;6:14.PubMedCrossRef

35.

Tarantino C, Paolella G, Cozzuto L, et al. miRNA 34a, 100, and 137 modulate differentiation of mouse embryonic stem cells. FASEB J. 2010;24(9):3255–63.PubMedCrossRef

36.

• Walsh T, McClellan JM, McCarthy SE, et al. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science. 2008;320(5875):539–43. This is one of the most important genome-wide CNV studies made in the field of SCZ.PubMedCrossRef

37.

Xu B, Roos JL, Levy S, et al. Strong association of de novo copy number mutations with sporadic schizophrenia. Nat Genet. 2008;40(7):880–5.PubMedCrossRef

38.

Anon. Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature. 2008;455(7210):237–41.CrossRef

39.

• Stefansson H, Rujescu D, Cichon S, et al. Large recurrent microdeletions associated with schizophrenia. Nature. 2008;455(7210):232–6. This is one of the most important genome-wide CNV study made in the field of SCZ.PubMedCrossRef

40.

Mulle JG, Dodd AF, McGrath JA, et al. Microdeletions of 3q29 confer high risk for schizophrenia. Am J Hum Genet. 2010;87(2):229–36.PubMedCrossRef

41.

McCarthy SE, Makarov V, Kirov G, et al. Microduplications of 16p11.2 are associated with schizophrenia. Nat Genet. 2009;41(11):1223–7.PubMedCrossRef

42.

Ingason A, Rujescu D, Cichon S, et al. Copy number variations of chromosome 16p13.1 region associated with schizophrenia. Mol Psychiatry. 2009;16(1):17–25.

43.

•• Craddock N, Hurles ME, Cardin N, et al. Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature. 2010;464(7289):713–20. This study made by the WTCCC shows that the common CNVs are unlikely to contribute significantly to disease as they are already tagged by the SNPs.PubMedCrossRef

44.

Malhotra D, McCarthy S, Michaelson JJ, et al. High frequencies of de novo CNVs in bipolar disorder and schizophrenia. Neuron. 2011;72(6):951–63.PubMedCrossRef

45.

• Gauthier J, Champagne N, Lafreniere RG, et al. De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia. Proc Natl Acad Sci U S A. 2010;107(17):7863–8. This is the first study to report a de novo mutation in a gene and to associate this gene with the disease.PubMedCrossRef

46.

Tarabeux J, Champagne N, Brustein E, et al. De novo truncating mutation in Kinesin 17 associated with schizophrenia. Biol Psychiatry. 2010;68(7):649–56.PubMedCrossRef

47.

Gauthier J, Siddiqui TJ, Huashan P, et al. Truncating mutations in NRXN2 and NRXN1 in autism spectrum disorders and schizophrenia. Hum Genet. 2011;130(4):563–73.

48.

• Awadalla P, Gauthier J, Myers RA, et al. Direct measure of the de novo mutation rate in autism and schizophrenia cohorts. Am J Hum Genet. 2010;87(3):316–24. This study has shown that the de novo mutation rate is higher than expected in SCZ.PubMedCrossRef

49.

•• Girard SL, Gauthier J, Noreau A, et al. Increased exonic de novo mutation rate in individuals with schizophrenia. Nat Genet. 2011;43(9):860–3. This study has shown a higher than expected rate of de novo mutation as well as identified a strong enrichment in de novo truncating mutations.PubMedCrossRef

50.

•• Xu B, Roos JL, Dexheimer P, et al. Exome sequencing supports a de novo mutational paradigm for schizophrenia. Nat Genet. 2011;43(9):864–8. This study has shown a higher than expected rate of de novo mutation as well as identified a strong enrichment in nonsynonymous mutations.PubMedCrossRef

51.

O’Roak BJ, Deriziotis P, Lee C, et al. Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations. Nat Genet. 2011;43(6):585–9.PubMedCrossRef

52.

Vissers LE, de Ligt J, Gilissen C, et al. A de novo paradigm for mental retardation. Nat Genet. 2010;42(12):1109–12.PubMedCrossRef

Title: Schizophrenia Genetics: Putting All the Pieces Together
Authors: Simon L. Girard
Patrick A. Dion
Guy A. Rouleau
Publication date: 01-06-2012
Publisher: Current Science Inc.
Published in: Current Neurology and Neuroscience Reports / Issue 3/2012
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-012-0266-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Schizophrenia Genetics: Putting All the Pieces Together

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2012

Erratum to: Chemotherapy-Related Cognitive Dysfunction

What We Know about the Generation of Nystagmus and Other Ocular Oscillations: Are We Closer to Identifying Therapeutic Targets?

Molecular Therapies for Tuberous Sclerosis and Neurofibromatosis

Thyroid Eye Disease: Towards an Evidence Base for Treatment in the 21st Century

Papilledema: Are We Any Nearer to a Consensus on Pathogenesis and Treatment?

Temozolomide Dosing Regimens for Glioma Patients